Results 61 to 70 of about 29,549 (204)

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source

Clinical Significance of ROS1 Rearrangements in Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2013
Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in multiple malignancies, including non-small cell lung cancer (NSCLC).
Luting XU, Ruijing ZHAO, Zengjun DONG, Tienian ZHU   +3 more
doaj   +1 more source

Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing

Molecular Oncology, 2020
ROS1 gene rearrangements have been reported in diverse cancer types including non‐small‐cell lung cancer (NSCLC), and with a notably higher prevalence in lung adenocarcinoma.
Meiying Cui, Yuchen Han, Pan Li, Jianying Zhang, Qiuxiang Ou, Xiaoling Tong, Ruiying Zhao, Nan Dong, Xue Wu, Wencai Li, Guozhong Jiang   +10 more
doaj   +1 more source

A Catalog of 5’ Fusion Partners in ROS1-Positive NSCLC Circa 2020

JTO Clinical and Research Reports, 2020
ROS1 fusion–positive (ROS1+) NSCLC was discovered in 2007, the same year as the discovery of ALK-positive (ALK+) NSCLC but has trailed ALK+ NSCLC in terms of development.
Sai-Hong Ignatius Ou, MD PhD, Misako Nagasaka, MD   +1 more
doaj   +1 more source

Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer

Frontiers in Oncology, 2021
BackgroundAlthough C-ros oncogene 1 (ROS1) targeted therapies have demonstrated remarkable efficacy in ROS1-rearranged non-small cell lung cancer (NSCLC), patients inevitably develop resistance to ROS1-tyrosine kinase inhibitors (TKIs). Commonly acquired
Jiangping Yang, Ping Zhou, Min Yu, Yan Zhang   +3 more
doaj   +1 more source

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research [PDF]

, 2016
Accurate variant calling in next generation sequencing (NGS) is critical to understand cancer genomes better. Here we present VarDict, a novel and versatile variant caller for both DNA- and RNA-sequencing data.
Ahdesmaki, Miika, Barrett, J. Carl, Chapman, Brad, Dougherty, Brian, Dry, Jonathan R., Hofmann, Oliver, Johnson, Justin, Lai, Zhongwu, Markovets, Aleksandra, McEwen, Robert   +9 more
core   +2 more sources

Chinese pan‐cancer patient genomic characteristics: A comprehensive analysis based on the National Cancer Center–Clinical Diagnostics Knowledgebase real‐world clinical sequencing cohort

Interdisciplinary Medicine, EarlyView.
We assembled National Cancer Center–Clinical Diagnostics Knowledgebase, a clinical genomic knowledgebase of 6935 tumors with matched normal samples, revealing key somatic alterations and actionable variants (70.2% of the cohort). Enrichment of certain different gene mutations was observed between Chinese and American populations, along with a strong ...
Hongrui Li, Shun Wang, Guowei Zhao, Jiangtao Li, Xin Li, Bingning Wang, Yi Zhang, Mengfei Yao, Lei Guo, Jianming Ying, Wenbin Li   +10 more
wiley   +1 more source

Small Nucleotide Variant Analysis Using RNA Fusion Panel (SMURF): Making the Most of RNAseq Data in Solid Tumours

Journal of Clinical Laboratory Analysis, EarlyView.
RNA‐based fusion panels using targeted next‐generation sequencing of formalin‐fixed paraffin‐embedded (FFPE) tumour tissue specimens have been used for a few years from patients with various tumour types to detect rearrangements/fusions. Using the bioinformatic approaches the data obtained from RNA sequencing (RNAseq) can also be used for small ...
Pranav Dorwal, Julie Robin, Broden Krause, Patricia Pyrchla, Bin Yuan, Robert Quach, Anna Fong Na Goh, Pamela Htain, Noel Djitro, Amit Kumar, Liyan Song, Priscillia Siswara, Suzanne Svobodova, Peter Kaub, Beena Kumar   +14 more
wiley   +1 more source

Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment

Frontiers in Oncology, 2022
BackgroundThe clinical significance of majority oncogenic novel fusions is still unknown due to scarcity. Reciprocal ROS1 translocation is a rare form of ROS1 fusion and has not yet been clearly analyzed.Case presentationA 44-year-old Chinese woman with ...
Xugang Zhang, Baoming Wang, Chunyang Wang, Chengde Liao, Shiping Wang, Ran Cao, Tonghui Ma, Kun Wang   +7 more
doaj   +1 more source

Identification and quantification of anthocyanins in transgenic purple tomato [PDF]

, 2016
Citation: Su, X., Xu, J., Rhodes, D., Shen, Y., Song, W., Katz, B., … Wang, W. (2016). Identification and quantification of anthocyanins in transgenic purple tomato. Food Chemistry, 202, 184–188. https://doi.org/10.1016/j.foodchem.2016.01.128Anthocyanins
Bae, Benjamin Katz, Bognar, Bovy, Bowen-Forbes, Butelli, Davina Rhodes, Delgado-Vargas, Gonzali, Holton, Hyun, Jianteng Xu, Jing, John Tomich, Khachik, Lim, Lim, Lukaszewicz, Mathews, Mes, Pannellini, Schijlen, Seeram, Tanaka, Wang, Wang, Wang, Wedick, Weiqun Wang, Weixing Song, Wu, Xiaoyu Su, Xu, Xu, Yanting Shen   +34 more
core   +1 more source